newsfilter
← Latest News
GlobeNewswire·

Eikon Therapeutics Reports First Quarter 2026 Financial Results and Provides Clinical Updates

  • Eikon Therapeutics reported a cash, cash equivalents, and marketable securities balance of $596 million as of March 31, 2026.
  • The company expects its current cash position to fund operations through the second half of 2027.
  • Eikon highlighted three priority oncology programs: EIK1001 (TLR7/8 agonist), EIK1003 (selective PARP1 inhibitor), and EIK1005 (WRN helicase inhibitor).
  • Six abstracts covering new safety, tolerability, and efficacy data for lead programs were accepted for the ASCO annual meeting.
  • EIK1001 Phase 2 data includes interim readouts for non-squamous and squamous NSCLC cohorts, with ongoing Phase 2/3 trials in melanoma \& stage 4 NSCLC.
  • EIK1003 Phase 1/2 trial dose escalation is complete for multiple cohorts, the first patient is dosed in a Phase 2 optimization trial, and global site selection is underway for Cohort 1D.
  • EIK1005 Phase 1/2 trial for advanced solid tumors began dosing in February 2026.
  • Research \& Development expenses rose to $70 million in Q1 2026 from $56.6 million in Q1 2025, driven by clinical trial acceleration \& a $5 million milestone payment to Impact Therapeutics.
  • General \& Administrative expenses increased to $17.3 million in Q1 2026 from $14.8 million in Q1 2025 due to higher depreciation, professional fees, insurance, \& recruitment costs.
  • Net loss for Q1 2026 was $83 million, compared to $74.5 million in the prior-year period.
  • CEO Roger M. Perlmutter is scheduled to present at the Bank of America Securities 2026 Global Healthcare Conference on May 12, 2026.
  • A manuscript detailing the use of single molecule tracking to advance chemical discovery was published in the Journal of Medicinal Chemistry.